DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases.
Ligthart S, Marzi C, Aslibekyan S, Mendelson MM, Conneely KN, Tanaka T, Colicino E, Waite LL, Joehanes R, Guan W, Brody JA, Elks C, Marioni R, Jhun MA, Agha G, Bressler J, Ward-Caviness CK, Chen BH, Huan T, Bakulski K, Salfati EL, WHI-EMPC Investigators, Fiorito G, CHARGE epigenetics of Coronary Heart Disease, Wahl S, Schramm K, Sha J, Hernandez DG, Just AC, Smith JA, Sotoodehnia N, Pilling LC, Pankow JS, Tsao PS, Liu C, Zhao W, Guarrera S, Michopoulos VJ, Smith AK, Peters MJ, Melzer D, Vokonas P, Fornage M, Prokisch H, Bis JC, Chu AY, Herder C, Grallert H, Yao C, Shah S, McRae AF, Lin H, Horvath S, Fallin D, Hofman A, Wareham NJ, Wiggins KL, Feinberg AP, Starr JM, Visscher PM, Murabito JM, Kardia SL, Absher DM, Binder EB, Singleton AB, Bandinelli S, Peters A, Waldenberger M, Matullo G, Schwartz JD, Demerath EW, Uitterlinden AG, van Meurs JB, Franco OH, Chen YI, Levy D, Turner ST, Deary IJ, Ressler KJ, Dupuis J, Ferrucci L, Ong KK, Assimes TL, Boerwinkle E, Koenig W, Arnett DK, Baccarelli AA, Benjamin EJ, Dehghan A. · 2016
Read DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. by Ligthart S, Marzi C, Aslibekyan S, Mendelson MM, Conneely KN, Tanaka T, Colicino E, Waite LL, Joehanes R, Guan W, Brody JA, Elks C, Marioni R, Jhun MA, Agha G, Bressler J, Ward-Caviness CK, Chen BH, Huan T, Bakulski K, Salfati EL, WHI-EMPC Investigators, Fiorito G, CHARGE epigenetics of Coronary Heart Disease, Wahl S, Schramm K, Sha J, Hernandez DG, Just AC, Smith JA, Sotoodehnia N, Pilling LC, Pankow JS, Tsao PS, Liu C, Zhao W, Guarrera S, Michopoulos VJ, Smith AK, Peters MJ, Melzer D, Vokonas P, Fornage M, Prokisch H, Bis JC, Chu AY, Herder C, Grallert H, Yao C, Shah S, McRae AF, Lin H, Horvath S, Fallin D, Hofman A, Wareham NJ, Wiggins KL, Feinberg AP, Starr JM, Visscher PM, Murabito JM, Kardia SL, Absher DM, Binder EB, Singleton AB, Bandinelli S, Peters A, Waldenberger M, Matullo G, Schwartz JD, Demerath EW, Uitterlinden AG, van Meurs JB, Franco OH, Chen YI, Levy D, Turner ST, Deary IJ, Ressler KJ, Dupuis J, Ferrucci L, Ong KK, Assimes TL, Boerwinkle E, Koenig W, Arnett DK, Baccarelli AA, Benjamin EJ, Dehghan A. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5151130.txt.
Introduction
Symen Ligthart and a very large team of co-authors hunted DNA methylation marks tied to inflammation, reporting in Genome Biology in 2016. Chronic low-grade inflammation, measured by the blood protein CRP, feeds many complex diseases. The team scanned chemical marks across the genome in 8,863 Europeans, then checked the hits in 4,111 African Americans.
They found 218 marked sites tied to CRP levels, of which 58 sites repeated in the second group. Many of those sites also tracked with gene activity, nearby DNA variants, and heart and metabolic conditions. A combined score of the confirmed sites explained up to six percent of the person-to-person spread in CRP, beyond what known genes explain. The authors offer the new loci as leads for anti-inflammatory drug hunting.
Catalog record
| CREATOR | Ligthart S, Marzi C, Aslibekyan S, Mendelson MM, Conneely KN, Tanaka T, Colicino E, Waite LL, Joehanes R, Guan W, Brody JA, Elks C, Marioni R, Jhun MA, Agha G, Bressler J, Ward-Caviness CK, Chen BH, Huan T, Bakulski K, Salfati EL, WHI-EMPC Investigators, Fiorito G, CHARGE epigenetics of Coronary Heart Disease, Wahl S, Schramm K, Sha J, Hernandez DG, Just AC, Smith JA, Sotoodehnia N, Pilling LC, Pankow JS, Tsao PS, Liu C, Zhao W, Guarrera S, Michopoulos VJ, Smith AK, Peters MJ, Melzer D, Vokonas P, Fornage M, Prokisch H, Bis JC, Chu AY, Herder C, Grallert H, Yao C, Shah S, McRae AF, Lin H, Horvath S, Fallin D, Hofman A, Wareham NJ, Wiggins KL, Feinberg AP, Starr JM, Visscher PM, Murabito JM, Kardia SL, Absher DM, Binder EB, Singleton AB, Bandinelli S, Peters A, Waldenberger M, Matullo G, Schwartz JD, Demerath EW, Uitterlinden AG, van Meurs JB, Franco OH, Chen YI, Levy D, Turner ST, Deary IJ, Ressler KJ, Dupuis J, Ferrucci L, Ong KK, Assimes TL, Boerwinkle E, Koenig W, Arnett DK, Baccarelli AA, Benjamin EJ, Dehghan A. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases By Symen Ligthart, Carola Marzi, Stella Aslibekyan, Michael M. Mendelson, Karen N. Conneely, Toshiko Tanaka, Elena Colicino, Lindsay L. Waite, Roby Joehanes, Weihua Guan, Jennifer A. Brody, Cathy Elks Published in: Genome Biology DOI: 10.1186/s13059-016-1119-5 ABSTRACT Background Chronic low-grade inflammation reflects a subclinical immune response implicated in the pathogenesis of complex diseases. Identifying genetic loci where DNA methylation is associated with chronic low-grade inflammation may reveal novel pathways or therapeutic targets for inflammation. Results We performed a meta-analysis of epigenome-wide association studies (EWAS) of serum C-reactive protein (CRP), which is a sensitive marker of low-grade inflammation, in a large European population (n = 8863) and trans-ethnic replication in African Americans (n = 4111). We found differential methylation at 218 CpG sites to be associated with CRP (P < 1.15 × 10–7) in the discovery panel of European ancestry and replicated (P < 2.29 × 10–4) 58 CpG sites (45 unique loci) among African Americans. To further characterize the molecular and clinical relevance of the findings, we examined the association with gene expression, genetic sequence variants, and clinical outcomes. DNA methylation at nine (16%) CpG sites was associated with whole blood gene expression in cis (P < 8.47 × 10–5), ten (17%) CpG sites were associated with a nearby genetic variant (P < 2.50 × 10–3), and 51 (88%) were also associated with at least one related cardiometabolic entity (P < 9.58 × 10–5). An additive weighted score of replicated CpG sites accounted for up to 6% inter-individual variation (R2) of age-adjusted and sex-adjusted CRP, independent of known CRP-related genetic variants. Conclusion We have completed an EWAS of chronic low-grade inflammation and identified many novel genetic loci underlying inflammation that may serve as targets for the development of novel therapeutic interventions for inflammation. Electronic supplementary material The online version of this article (doi:10.1186/s13059-016-1119-5) contains supplementary material, which is available to authorized users. BACKGROUND Chronic low-grade inflammation is a complex immune response that plays an important role in the pathogenesis of multiple chronic diseases, including diabetes and cardiovascular disease [1, 2]. C-reactive protein (CRP) is a sensitive marker of chronic low-grade inflammation in community-dwelling adults [3] and is associated in population-based studies with an increased risk of incident coronary heart disease (CHD), stroke, and non-vascular mortality [4]. Several pathways have been identified for chronic low-grade inflammation [1, 5] and genetic studies have found candidate loci through discovery of genetic sequence determinants of circulating CRP levels [6]. However, most of the molecular mechanisms underlying inter-individual variation in inflammation in the general population and the inter-relation with complex diseases remain to be elucidated. Epigenetic modifications comprise biochemical alterations to the genome that leave the underlying nucleic acid sequence unchanged but can affect phenotypic expression. DNA methylation is a pivotal and stable epigenetic mechanism whereby a methyl group is attached to the DNA sequence, most often a cytosine nucleotide that neighbors a guanine nucleotide. DNA methylation is affected by both genetic and environmental factors and regulates gene expression and chromosome stability [7]. Investigating DNA methylation in chronic low-grade inflammation may point to functional epigenetic changes that occur in the context of inflammation. We performed the first meta-analysis of epigenome-wide association studies (EWAS) of methylation of DNA on chronic low-grade inflammation using CRP as a sensitive inflammatory biomarker (Fig. 1). We first conducted a discovery meta-analysis, comprising 8863 participants of European ancestry. Since race or ethnicity may affect epigenetic associations [8], we conducted trans-ethnic replication in 4111 individuals of African-American ancestry. We further investigated the association between replicated DNA methylation sites and both cis- gene expression and genetic variants. Finally, differentially methylated CpG sites were examined for association with cardiometabolic phenotypes to study potential epigenetic links between inflammation and cardiometabolic diseases.Fig. 1 Illustration of overall study flow RESULTS Clinical characteristics The nine participating discovery (n = 8863) and four replication cohorts (n = 4111) and the clinical characteristics of the participants are presented in Table 1 (further details, Additional file 1: Table S1). The mean age in the participating studies ranged from 41 years in the Grady Trauma Project (GTP) cohort to 87 years in Lothian Birth Cohort (LBC) 1921. The majority (54%) of the samples were from women. Some of the cohorts differed based on selection criteria for entry into the study. The Normative Aging Study (NAS) only included men, while the Women’s Health Initiative (WHI) only included women. Mean serum CRP levels (SD) ranged from 2.3 (3.7) mg/L in the Kooperative Gesundheitsforschung in der Region Augsburg (KORA) study to 7.2 (8.4) mg/L in the African-American CHD cases of WHI.Table 1Characteristics of the discovery (n = 8863) and replication (n = 4111) studiesStudynCountryAge (years)Women (%)CRP (mg/L)BMI (kg/m2)Discovery (European) CHS187USA76 (5)566.6 (11.0)31 (6) EPIC-Norfolk1287UK60 (9)543.3 (5.4)27 (4) FHS2427USA66 (9)523.1 (6.7)28 (5) InCHIANTI498Italy63 (16)553.2 (3.5)27 (4) KORA1700Germany61 (9)512.3 (3.7)28 (5) LBC 1921169UK87 (0)543.7 (8.4)26 (4) LBC 1936296UK70 (1)505.3 (6.8)28 (4) NAS648USA73 (7)03.3 (6.1)28 (4) Rotterdam702Netherlands60 (8)542.7 (4.7)28 (5) WHI controls471USA68 (6)1003.8 (5.5)28 (6) WHI cases478USA69 (6)1004.9 (6.4)29 (6)Replication (African American) ARIC2264USA56 (6)645.9 (7.8)30 (6) CHS193USA73 (5)655.2 (5.6)29 (5) GENOA939USA66 (8)716.7 (12.3)31 (6) GTP112USA41 (13)705.9 (8.1)33 (8) WHI controls309USA62 (6)1006.1 (7.5)31 (7) WHI cases294USA64 (7)1007.2 (8.4)32 (6)Characteristics are mean (SD), unless otherwise specified ARIC Atherosclerosis Risk in Communities, BMI body mass index, CHS Cardiovascular Health Study, CRP C-reactive protein, EPIC-Norfolk European Prospective Investigation into Cancer and Nutrition Norfolk, FHS Framingham Heart Study, GENOA Genetic Epidemiology Network of Arteriopathy, InCHIANTI Invecchiare in Chianti, KORA Kooperative Gesundheitsforschung in der Region Augsburg, LBC Lothian Birth Cohort, NAS Normative Aging Study, UK United Kingdom, USA United States of America, WHI Women’s Health Initiative Discovery meta-analysis We identified 218 CpG sites significantly associated (P < 1.15 × 10−7) with CRP in the meta-analysis of European participants, adjusted for age, sex, white blood cell proportions, technical covariates, smoking, and body mass index (BMI) (Manhattan and QQ-plot, Fig. 2, Additional file 2: Table S2, and Additional file 3: Table S3). Serum CRP was positively associated with 125 CpG sites and negatively associated with 93. The top CpG site was cg10636246 at 1q23.1 located within 1500 bp of the transcription start site of Absent in melanoma 2 (AIM2) (effect size = −0.0069, P = 2.53 × 10−27), an interferon-gamma-induced protein involved in the innate immune response by inducing caspase-1-activating inflammasome formation in macrophages.Fig. 2 a Manhattan plot depicting the –log10(P values) of the associations between all CpG sites and CRP, adjusted for age, sex, BMI, cell distributions, technical covariates, and smoking. The dotted lines indicate the Bonferroni threshold of 1.15 × 10−7 for significance. The red dots indicate positive significant associations between methylation and CRP, the blue dots indicate negative significant associations. b QQ plot showing observed vs. expected − log10(P values) for association at all CpG sites Replication meta-analysis Of the 218 CpG sites significantly associated with CRP in our discovery meta-analysis, 58 replicated (P < 2.29 × 10−4) in a trans-ethnic replication meta-analysis of 4111 individuals of African-American ancestry (Table 2). The replicated CpG sites annotated to 45 separate loci. The most significant CpG site in the discovery panel (cg10636246; AIM2) was also strongly related to serum CRP in individuals of African-American ancestry (effect size = −0.0081, P = 6.31 × 10−9).